These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34454870)

  • 1. The case of complement inhibitors.
    Noris M
    Adv Biol Regul; 2021 Aug; 81():100822. PubMed ID: 34454870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double edged-sword - The Complement System during SARS-CoV-2 infection.
    Santiesteban-Lores LE; Amamura TA; da Silva TF; Midon LM; Carneiro MC; Isaac L; Bavia L
    Life Sci; 2021 May; 272():119245. PubMed ID: 33609539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19.
    Adesanya TMA; Campbell CM; Cheng L; Ogbogu PU; Kahwash R
    J Clin Immunol; 2021 May; 41(4):729-732. PubMed ID: 33474624
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade.
    Vitiello A; La Porta R; D'Aiuto V; Ferrara F
    Hum Immunol; 2021 Apr; 82(4):264-269. PubMed ID: 33632561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the COVID-19 thrombotic catastrophe complement-connected?
    Conway EM; Pryzdial ELG
    J Thromb Haemost; 2020 Nov; 18(11):2812-2822. PubMed ID: 32762081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins.
    Ali YM; Ferrari M; Lynch NJ; Yaseen S; Dudler T; Gragerov S; Demopulos G; Heeney JL; Schwaeble WJ
    Front Immunol; 2021; 12():714511. PubMed ID: 34290717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement as a target in COVID-19?
    Risitano AM; Mastellos DC; Huber-Lang M; Yancopoulou D; Garlanda C; Ciceri F; Lambris JD
    Nat Rev Immunol; 2020 Jun; 20(6):343-344. PubMed ID: 32327719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of Complement Imbalance in COVID-19: A Molecular Mechanistic Discussion on the Importance of Complement Balance.
    Torabizadeh M; Modaresi Asfeh H; Deris Zayeri Z; Dominique C; Kazemi H; Saki N
    Iran J Immunol; 2023 Sep; 20(3):247-261. PubMed ID: 37545318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option.
    Stahel PF; Barnum SR
    Front Immunol; 2020; 11():1661. PubMed ID: 32733489
    [No Abstract]   [Full Text] [Related]  

  • 10. Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review.
    Fletcher-Sandersjöö A; Bellander BM
    Thromb Res; 2020 Oct; 194():36-41. PubMed ID: 32569879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terminal complement inhibition dampens the inflammation during COVID-19.
    Kulasekararaj AG; Lazana I; Large J; Posadas K; Eagleton H; Lord Villajin J; Zuckerman M; Gandhi S; Marsh JCW
    Br J Haematol; 2020 Aug; 190(3):e141-e143. PubMed ID: 32495372
    [No Abstract]   [Full Text] [Related]  

  • 12. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
    Mastaglio S; Ruggeri A; Risitano AM; Angelillo P; Yancopoulou D; Mastellos DC; Huber-Lang M; Piemontese S; Assanelli A; Garlanda C; Lambris JD; Ciceri F
    Clin Immunol; 2020 Jun; 215():108450. PubMed ID: 32360516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement inhibitors are not useful in secondary hemolytic uremic syndromes.
    Duineveld C; Wetzels JFM
    Kidney Int; 2019 Oct; 96(4):829-833. PubMed ID: 31543154
    [No Abstract]   [Full Text] [Related]  

  • 14. Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19.
    Satyam A; Tsokos MG; Brook OR; Hecht JL; Moulton VR; Tsokos GC
    Clin Immunol; 2021 May; 226():108716. PubMed ID: 33774179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyper-inflammation and complement in COVID-19.
    Pires BG; Calado RT
    Am J Hematol; 2023 May; 98 Suppl 4():S74-S81. PubMed ID: 36999459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19.
    Peerschke EI; Valentino A; So RJ; Shulman S; Ravinder
    Front Immunol; 2021; 12():716361. PubMed ID: 34491250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection.
    Sinkovits G; Mező B; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
    Front Immunol; 2021; 12():663187. PubMed ID: 33841446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation.
    Jarlhelt I; Nielsen SK; Jahn CXH; Hansen CB; Pérez-Alós L; Rosbjerg A; Bayarri-Olmos R; Skjoedt MO; Garred P
    Front Immunol; 2021; 12():767981. PubMed ID: 34804055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the Complement Pathway in Inflammatory Skin Diseases: A Focus on Hidradenitis Suppurativa.
    Ghias MH; Hyde MJ; Tomalin LE; Morgan BP; Alavi A; Lowes MA; Piguet V
    J Invest Dermatol; 2020 Mar; 140(3):531-536.e1. PubMed ID: 31870626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement C5 inhibition in patients with COVID-19 - a promising target?
    Peffault de Latour R; Bergeron A; Lengline E; Dupont T; Marchal A; Galicier L; de Castro N; Bondeelle L; Darmon M; Dupin C; Dumas G; Leguen P; Madelaine I; Chevret S; Molina JM; Azoulay E; Fremeaux-Bacchi V; Core Group
    Haematologica; 2020 Dec; 105(12):2847-2850. PubMed ID: 33256385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.